Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis

Abstract The IMpower trials reported significant effects of atezolizumab‐containing chemotherapies on Caucasian patients. Chinese patients differ from their Western counterparts in terms of driver mutations, etiologies, and regimen tolerance. In China, atezolizumab‐containing chemotherapies are not...

Полное описание

Библиографические подробности

Главные авторы:	Yingkai Chen, Shizhou Kang, Ming Yan
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2022-06-01
Серии:	Pharmacology Research & Perspectives
Предметы:	atezolizumab carboplatin chemotherapy immunotherapies nab‐paclitaxel non‐small‐cell lung cancer
Online-ссылка:	https://doi.org/10.1002/prp2.941
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!